Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean glycol lactate and lactic acid?
Displaying drugs 2176 - 2200 of 15113 in total

Binimetinib

Binimetinib, also known as Mektovi, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with Encorafenib.[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of Encorafenib and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients...
Approved
Investigational
Matched Description: … ] and binimetinib (BRAFTOVI and MEKTOVI, from Array BioPharma Inc.) in combination for patients with ... Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase ... [A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Xamoterol

Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function in studies with heart failure patients. It modulates the sympathetic control of the heart but has no agonist action on β2-adrenoceptors.
Approved
Matched Description: … Xamoterol is a β1-adrenoceptor partial agonist that has shown to improve systolic and diastolic function …

Dexrazoxane

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and...
Approved
Withdrawn
Matched Description: … prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy. ... [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the …

Rolapitant

Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its ligand Substance P, which is released in the gut...
Approved
Investigational
Matched Description: … Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated ... Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and ... By blocking Substance P from interacting with NK-1 receptors in the gut and the central nervous system …
Matched Categories: … Antiemetics and Antinauseants ... Alimentary Tract and Metabolism …

NADH

NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by...
Approved
Nutraceutical
Matched Iupac: … [(2R,3S,4R,5R)-5-(3-carbamoyl-1,4-dihydropyridin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy})phosphinic acid …
Matched Description: … electron carrier by being alternately oxidized (NAD+) and reduced (NADH). ... It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an ... NADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide …
Matched Categories: … Enzymes and Coenzymes ... Nucleic Acids, Nucleotides, and Nucleosides …

Somatrem

Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short...
Approved
Investigational
Withdrawn
Matched Description: … Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Alatrofloxacin

Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid …

Cefamandole nafate

Approved
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid …

Carboprost tromethamine

A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Approved
Matched Iupac: … -7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hept-5-enoic acid …
Matched Description: … A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy …
Matched Categories: … Genito Urinary System and Sex Hormones …

Elivaldogene autotemcel

Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy, an X-linked genetic disorder characterized by missing or non-functional ABCD1 gene that codes for ALDP. ALDP is a key protein that normally...
Approved
Matched Description: … destruction of myelin, which is an insulating layer and essential component of nerves. ... Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and ... It was approved by the European Commission in July 2021 under the market name Skysona, and was later …
Matched Categories: … Cellular and Gene Therapy ... Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …

Tesamorelin

Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Approved
Investigational
Matched Description: … Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …

Brivudine

Brivudine is used in the treatment of herpes zoster. Although not approved in the U.S. or Canada, it is approved in several European countries.
Approved
Investigational
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides ... Nucleosides and Nucleotides Excl. Reverse Transcriptase Inhibitors …

Magnesium glycinate

Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
Approved

Cladribine

Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia....
Approved
Investigational
Matched Description: … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and ... [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …

Colistin

Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Description: … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Lomustine

An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Description: … An alkylating agent of value against both hematologic malignancies and solid tumors. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Salmon calcitonin

Synthetic peptide, 32 residues long formulated as a nasal spray.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Parathyroid and Antiparathyroid Agents …

Cilostazol

Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing...
Approved
Investigational
Matched Description: … Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions ... Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been …
Matched Categories: … Blood and Blood Forming Organs …

Bucetin

Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.
Approved
Withdrawn
Matched Description: … Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn …

Cerliponase alfa

Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Relatlimab

Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Idecabtagene vicleucel

Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …

Pegvisomant

Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Elosulfase alfa

Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over...
Approved
Investigational
Matched Description: … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Chondroitinases and Chondroitin Lyases …

Sacrosidase

Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Displaying drugs 2176 - 2200 of 15113 in total